Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

Scot H. Simpson, Sumit R. Majumdar, Ross T. Tsuyuki, Dean T. Eurich and Jeffrey A. Johnson
CMAJ January 17, 2006 174 (2) 169-174; DOI: https://doi.org/10.1503/cmaj.050748
Scot H. Simpson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sumit R. Majumdar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross T. Tsuyuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean T. Eurich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey A. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Over the past 30 years, the relation between use of sulfonylureas to treat type 2 diabetes and the risk of cardiovascular events has been vigorously debated. The purpose of this study was to determine if the risk of death changes with level of exposure to sulfonylurea drugs.

Methods: This was a retrospective, inception cohort study using administrative data from Saskatchewan Health (1991– 1999). The 5795 subjects, identified by their first-ever dispensation for an oral antidiabetic agent, were grouped according to their use of such agents during follow-up. Potential subjects using insulin or combination therapy were excluded. Exposure level was defined by daily dose and degree of adherence. Separate multivariate Cox proportional-hazard models were constructed for each monotherapy group and used to calculate the risk of death associated with higher versus lower exposure category. Disease severity indicators were identified among the administrative data and entered as covariates in each model. The main outcomes were all-cause mortality and death from an acute ischemic event.

Results: The mean age of the cohort members was 66.3 (standard deviation [SD] 13.4) years; 43.4% were female; and their mean duration of follow-up was 4.6 (SD 2.1) years. First-generation sulfonylureas were used exclusively by 120 subjects; glyburide, by 4138; and metformin, by 1537. A greater risk of death was associated with higher daily doses of the first-generation sulfonylureas (adjusted hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.0–4.7) and glyburide (HR 1.3, 95% CI 1.2–1.4), but not metformin (HR 0.8, 95% CI 0.7–1.1). Similar associations were observed for death caused by an acute ischemic event.

Interpretation: Higher exposure to sulfonylureas was associated with increased mortality among patients newly treated for type 2 diabetes. The same relation was not observed with metformin. This implies that the manner in which blood glucose concentration is lowered may be as important as achieving recommended glucose targets.

View Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (2)
CMAJ
Vol. 174, Issue 2
17 Jan 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
Scot H. Simpson, Sumit R. Majumdar, Ross T. Tsuyuki, Dean T. Eurich, Jeffrey A. Johnson
CMAJ Jan 2006, 174 (2) 169-174; DOI: 10.1503/cmaj.050748

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
Scot H. Simpson, Sumit R. Majumdar, Ross T. Tsuyuki, Dean T. Eurich, Jeffrey A. Johnson
CMAJ Jan 2006, 174 (2) 169-174; DOI: 10.1503/cmaj.050748
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue • Dans ce numéro
  • Highlights of this issue • Dans ce numéro
  • Do sulfonylurea drugs increase the risk of cardiac events?
  • PubMed
  • Google Scholar

Cited By...

  • Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
  • Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
  • Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
  • Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
  • Cardiovascular Safety Profile of Currently Available Diabetic Drugs
  • Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
  • Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
  • Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes: Reconciling the Recent Clinical Trial Data
  • Muscle Dysfunction Caused by a KATP Channel Mutation in Neonatal Diabetes Is Neuronal in Origin
  • Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
  • Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
  • Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
  • Changes in Adherence to Evidence-Based Medications in the First Year After Initial Hospitalization for Heart Failure: Observational Cohort Study From 1994 to 2003
  • Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted?
  • Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
  • Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
  • Evidently...
  • Other articles noted
  • Patient characteristics not described
  • Do Sulfonylureas Increase Mortality?
  • Do sulfonylurea drugs increase the risk of cardiac events?
  • Google Scholar

More in this TOC Section

  • Emergency department use following incentives to provide after-hours primary care: a retrospective cohort study
  • Physician choices in pulmonary embolism testing
  • Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study
Show more Research

Similar Articles

Collections

  • Topics
    • Drugs: cardiovascular system
    • Diabetes

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire